Skip to main content
. 2023 Sep 28;12(10):1490. doi: 10.3390/antibiotics12101490

Figure 4.

Figure 4

Day 35 implant CFUs. On POD 35, animals were sacrificed, implants were harvested, and CFUs were enumerated. (A) POD 35 ex vivo mean implant CFUs. There was a 4-log reduction in average implant CFUs in the TRL1068+vancomycin group relative to the infected control group (6.17 × 10−1 vs. 1.03 × 104, respectively; p < 0.0001), and a 3.3-log reduction in average implant CFUs in the TRL1068+vancomycin group relative to the vancomycin only group (6.17 × 10−1 vs. 1.13 × 104, respectively; p = 0.003). (B) Implant infection. Pearson’s Chi-square test showed a statistical relationship between treatment and infection status for the implants (χ2 [df = 3, N = 78] = 18.73; p < 0.001). The TRL1068+Vanc group had significantly lower proportion of infected implants (1/27, 3.7%; p < 0.05) compared to the infected control (8/12, 66.7%) and the Vanc (5/12, 41.7%) groups. ns = not significant, * p < 0.05, ** p < 0.005, **** p < 0.0001.